Imaging Tau Deposition in the Brain of Elderly Subjects

Healthy Clinical Trial

— Add-Tau  

Official title:

Imaging Tau Deposition in the Brain of Elderly Subjects

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02958670
• Other study ID #: KEK-ZH_Nr_2016-01079_V10.0
• Status: Active, not recruiting
• Phase: N/A
• Start date: November 2016
• Est. completion date: December 2029

Study information

• Verified date: November 2023
• Source: University of Zurich
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cerebral accumulation of tau and beta-amyloid are major factors of Alzheimer's disease pathology. A novel Positron Emission Tomography (PET) tracer (18-F-AV-1451) now offers the ability to study tau protein deposition in vivo in subjects, in which information on cerebral amyloid deposition has already been gathered. This enables to study effects of tau deposition on neuronal integrity, their relation to effects of beta-amyloid deposition and how this contributes to cognitive impairment or well-being in the elderly.

Description:

This is a single-center exploratory observational clinical study combining cross sectional and longitudinal aspects. It contains 18F-AV-1451-PET as an intervention. The primary objective is to measure tau deposition with 18-F-AV1451-PET based on voxel wise or volume based quantitative assessments and to study the effects of Tau deposition on the organism by identification of factors correlating to the measured tau deposition. Study participants will be followed for up to 8 years. To date cerebral tau pathology in vivo was only estimated by cerebrospinal fluid (CSF) tau or CSF phospho-tau which precludes a study of topical distribution and interplay with Abeta pathology. 18F-AV-1451 offers the chance to visualize tau pathology and to study effects of tau on brain structure, brain physiology and cognitive function. Ideally, these effects are studied in well characterized individuals in whom other important pathological factors are already known. We therefore plan to study tau pathology measured by 18F-AV-1451 in subjects with already existing data on cerebral amyloid deposition (11C-Pittsburgh Compound C, Flutemetamol). We will be able to relate tau pathology to past and prospective cognitive performance assessed by a detailed neuro¬psychological examination, and we will be able to investigate whether cerebral tau pathology is reflected by peripheral blood biomarkers. For this purpose we will include elderly subjects with various degrees of cognitive performance (cognitively healthy, mild cognitive impairment, dementia) and various degrees of cerebral amyloid deposition (dichotomized or quantitative). We will also include Frontotemporal Lobar Degeneration (FTLD) cases to study tau effects in neurodegenerative disease in the absence of beta-amyloid. Our hypotheses are the following: 1. We assume that it is possible to identify tau deposition in subjects with and without cerebral Abeta deposition. 2. We hypothesize that tau-deposition will be associated with structural and physiological brain changes and that there are synergistic effects of the amount of tau and Abeta pathology on certain brain regions and on cognitive function.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 141
• Est. completion date: December 2029
• Est. primary completion date: December 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

1. Subject belongs to one of the following groups:

• No cognitive impairment
• Mild cognitive impairment according to Winblad et al., 2004
• Clinical diagnosis of dementia due to Alzheimer's disease compatible with DSM IV criteria or revised NINCDS-ADRDA criteria
• Evidence of neurodegenerative disease other than AD

2. Written informed consent approved by the regulatory authorities

3. Age = 50 years, women must be without childbearing potential

4. Pre-existing PET information (11C-Pittsburgh Compound B, 18F-Flutemetamol) on cerebral amyloid deposition

5. German speaking or sufficient knowledge of German language to perform study assessments

6. Subject is willing and able to name an informant who can give adequate information on the scales where informant input is required

Exclusion Criteria:

1. Evidence for cognitive impairment mainly attributed to a non-neurodegenerative underlying medical condition (e.g. medication, brain tumor, severe heart insufficiency, hepatic encephalopathy)

2. Evidence of larger cerebral infarcts, or lacunes in critical memory structures

3. Disease or other condition with a potential to interfere with study participation

4. Ongoing infection with human immunodeficiency virus (HIV) or any hepatitis virus

5. Active, acute or chronic leukemia

6. Severe illness likely to cause disability that interferes with study procedures in the following years

7. Evidence of acute psychiatric disease (upon clinical decision) which may be a cause of cognitive impairment. Patients with a history of major depression under stable medication may be included. Patients with low dose intake of benzodiazepines may also be included upon clinician's decision

8. Previous or current participation in anti-beta-amyloid or anti-tau therapeutic trials

9. MR exclusion criteria

10. PET exclusion criteria

11. Contraindications against venous puncture

12. Other condition that might pose a risk to the study subject in the opinion of the investigator

13. Exclusion criteria for subproject CSF sampling

Related Conditions & MeSH terms

• Alzheimer Disease
• Cognitive Dysfunction
• Healthy
• Mild Cognitive Impairment
• Neurocognitive Disorders

Intervention

Other:
• 18F-AV-1451 (Tau-PET tracer)
Single i.v. administration of 18F-AV-1451 (Tau-PET tracer) and consecutive Positron-Emission-Tomography-Scan

Locations

Country	Name	City	State
Switzerland	Institute for Regenerative Medicine (IREM)	Schlieren	Zurich

Sponsors (3)

Lead Sponsor	Collaborator
University of Zurich	Avid Radiopharmaceuticals, Swiss Federal Institute of Technology

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Transition from one clinical state to another (e.g. MCI to AD) worsening of clinical function measured as an increase in CDRSOB-score of one		up to two years
Other	Neuropsycholgical test performance		up to two years
Other	Magnetresonance Tomography (MR) readouts		Baseline and two years
Other	Blood and CSF-biomarker-read outs		Baseline and two years
Primary	Volume of Interest (VOI) or Voxel based assessment of 18F-AV-1451-PET-signal		Baseline measurement